Arcturus Therapeutics (ARCT) closed the last trading session at $10.84, gaining 5.2% over the past four weeks, but there ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. | San Diego ...

Q1 2025 Management View Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to forthcoming clinical data for both the ARCT-032 cystic ...

In CF, Arcturus is advancing an inhalable mRNA therapy, ARCT-032, for which it is running a Phase II trial in patients who ...

GameSpot may get a commission from retail offers.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company specializing in mRNA therapeutics and vaccines, stands at a critical juncture as it navigates a rapidly ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate. Arcturus on Thursday said the designation ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

There's a big diamond in the sky made by connecting the stars Arcturus, Spica, Denebola and Cor Caroli. Once found, you can ...

Payne reported the recent EU approval of KOSTAIVE, Arcturus' self-amplifying mRNA COVID-19 vaccine, and receipt of an initial milestone payment from CSL. He announced an upcoming marketing ...